anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A replacement handle for rowing exercise machines. The rowing machine handle described herein is a simple tool which can be added to existing machines to give the user greater feedback and control over training and exercise sessions, on a variety of rowing exercise machines, than is currently available. It is easy to use, and with included applications for mobile devices will help the user to create more effective training sessions and training programs. Said rowing machine handle can be used effectively by a wide range of users. Current rowing machine handles do not provide electronic feedback about the rowing motion or exercise performance. The above replacement handle will provide direct and immediate feedback to the user about his exercise session, including information about his rowing motion (technique) and his exercise performance (physiology).
<P>PROBLEM TO BE SOLVED: To provide a periodontal disease preventive which converts periodontal disease countermeasure from dental medical checkup or treatment being only a countermeasure after morbidity into a preventive countermeasure not causing morbidity; and its preparation method.  <P>SOLUTION: The periodontal disease preventive is characterized in that the ume flesh of pickled ume or dried pickled ume is miniaturized so as to be able to permeate together with saliva to periodentium between teeth and gum ridges. The ume flesh of pickled ume or dried pickled ume is only ume flesh from which seeds, perilla, and salted ume juice are separated and removed; and the miniaturization is carried out to an extent wherein the particle size of the ume flesh reaches 100 μm or less. The pickled ume or dried pickled ume is prepared by using only ume, perilla, kitchen salt, and white distilled liquor and without adding any other additive. The preparation method of the periodical disease preventive is characterized in that the ume flesh of pickled ume or dried pickled ume is miniaturized so as to be able to permeate to periodentium between teeth and gum ridges; and the miniaturization is carried out to an extent wherein the particle size of the ume flesh reaches 100 μm or less. The pickled ume or dried pickled ume is generated by using only ume, perilla, kitchen salt, and white distilled liquor and without adding any other additive.  <P>COPYRIGHT: (C)2007,JPO&INPIT
CNS stimulants, including lisdexamfetamine dimesylate capsules, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports and at the therapeutic dosages of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant. 

Careful observation for digital changes is necessary during lisdexamfetamine dimesylate treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for lisdexamfetamine dimesylate-treated patients who develop signs or symptoms of peripheral vasculopathy.
Patients assigned to this arm will receive SBRT followed by sintilimab. Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks. In the SBRT + PD-1 arm, sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
A hybrid nuclear fusion fast fission reactor is disclosed. The hybrid reactor may include an electrolyte solution comprised of PdCI2 a conductive salt and D2O, an anode of a noble metal, a cathode consisting of a conductive high Z (atomic number greater than 46) material wound around a deuteride-forming actinide nuclear fuel element, a power source providing constant current to the + anode and the - cathode, an applied power profile for fabricating the PdD nanoalloy, and a co-deposition of a PdD nanoalloy on to the high Z cathode winding as well as the nuclear fuel element. A preferred embodiment stablizes the actinide deuteride nuclear fuel element from hydrogen isotope de-loading. A preferred embodiment initiates deuterium-deuterium fusion in the deuterized fuel element and fissioning deuterized fuel element actinides. A preferred embodiment includes surrounding spent nuclear fuel elements with deuteride nuclear fuel elements that will fast fission the spent fuel elements. Another preferred embodiment includes surrounding the deuteride nuclear fuel elements with spent fuel elements as fast neutron reflectors that will also fission.
PURPOSE: To obtain a colloidally dispersible liq. active compd. compsn. which has stability, activity, etc., superior to those of a conventional aq. active compd. compsn. by compounding an active compd. being very slightly soluble in water, a specific vinylpyrrolidone-based copolymer, a surfactant, and optionally an additive and/or a solvent.  
     CONSTITUTION: This compsn. contains (A) an active compd. very slightly soluble in water, (B) a copolymer of vinylpyrrolidone and/or vinylcaprolactam and at least one hydrophobic monomer for decreasing the water solubility of the copolymer, (C) at least one surfactant, and optionally (D) an additive and/or a diluent. As ingredient A are listed dihydropyridine, azole, nitromethylene, arylpyrazoline, valineamide carbamate, benzothiophenecarboxamide, and benzoylurea. The compsn. is useful for producing drugs and plant-protecting compsns. 
     COPYRIGHT: (C)1995,JPO
The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg/kg to 18 mg/kg, preferably 8 to 12 mg/kg, more preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.
BACKGROUND: Obesity is associated with the development of polycystic ovarian syndrome (PCOS), a complex endocrine disorder. However, the correlation between body composition and PCOS in women has not been thoroughly investigated. This study aimed to examine body composition using bioelectrical impedance analysis (BIA) in women with and without PCOS in a population-based study within the Tehran Lipid and Glucose Study (TLGS).
METHODS: We conducted a cross-sectional study among non-menopausal women aged 18-45 who underwent BIA in phase VII of the TLGS. A total of 150 participants with PCOS and 240 without PCOS were included based on the Rotterdam criteria. Baseline demographic, anthropometric, laboratory, and body composition parameters were compared between the two groups.
RESULTS: The mean age was 33.7 ± 7.45 years in the PCOS group and 35.49 ± 7.05 years in the control group. The mean BMI was 27.0 ± 4.0 kg/m2 in the PCOS group and 27.1 ± 4.4 kg/m2 in the control group. No significant differences were found in body composition parameters between the two groups as assessed by BIA. Additionally, there were no correlations between body composition and hormone parameters in PCOS patients.
CONCLUSION: In this sample of non-referral patients with PCOS, the use of BIA did not provide added value beyond conventional anthropometric measures for assessing body composition. Further longitudinal research is needed to determine whether body composition analysis can enhance PCOS evaluation.
Fragile X Syndrome (FXS) is the leading monogenic cause of intellectual disability and autism and is associated with extremely high risk for early delays in speech and language. While early childhood is essential for speech and language development, neural mechanisms for language impairments have been studied entirely in older children and adults with FXS. Therefore, markers for speech and language impairments are unavailable in young children with FXS to predict severity, test potential mechanisms, and track response to intervention. The investigators have identified a hallmark brain-based phenotype of hyperresponsiveness to sounds in adolescents and adults with FXS. This fundamental alteration in cortical responses to sound could influence early language delays, but this phenotype has not been explored in infants or toddlers with FXS.

Specifically, in this study the investigators will use simultaneous EEG/fNIRS during presentation of simple speech, stories, and nonspeech sounds to quantify and localize auditory hypersensitivity and neural differentiation in 30 preschoolers with FXS. The investigators will assess specificity through comparison with 30 typically developing controls and 30 mental-age matched children with a history of premature birth and language delays.
There is a growing interest in the cardiometabolic benefits of various intermittent fasting paradigms (such as alternate day fasting and the 5:2 fast diet), where periods of normal energy intake are punctuated by periods of energy restriction or fasting. A recent alternative to these protocols is time-restricted feeding (TRF), which limits daily food/energy intake to a narrow window (typically 8 to 10h). The major strength of TRF is that it extends the duration of overnight fast without limiting normal calorie intake. Recent evidence from both animal and human studies have shown that habitual daily periods of fasting of as little as 16h can reduce fasting insulin and triglycerides levels, protect against excessive body weight gain in response to high fat and sucrose diets, better maintain fat-free mass, and improve beta-cell responsiveness. We recently completed a 2-week TRF intervention study using the 8h fed (between 8am and 4pm)/16h fast protocol in healthy individuals and found improvements in insulin sensitivity and skeletal muscle uptake of branched chain amino acids. As we did not make measurements of muscle protein synthesis, it is not known whether a single episode of prolonged overnight fast (\~16h) is sufficient to elicit improvements in insulin sensitivity and stimulate skeletal muscle protein synthesis in response to dietary protein ingestion. The aim of the proposed study is to investigate the effect of prolonged overnight fast (16h vs. 10h) on postprandial energy metabolism and skeletal muscle protein synthesis in healthy humans.
Study procedure will consist in 2-team (combined) LAR with transanal TME using laparoscopic abdominal assistance.Transanal TME is performed either at the same time or following the above steps. Transanal endoscopic TME dissection will proceed circumferentially until the peritoneal cavity is entered anteriorly. Following complete mobilization of the rectosigmoid, the specimen is extracted transanally or using a Pfannenstiel incision followed by colorectal anastomosis, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
After completion of the phone screen, eligible participants will be brought into the laboratory, given a description of the study, and assessed on inclusion and exclusion criteria by research personnel. Details pertaining to the cognitive measures, pain measures, and methadone manipulation will be discussed and informed consent will be obtained along with a signed release to allow study personnel to monitor opioid maintenance. Information on medical, psychiatric and drug use histories will be collected. Individuals with a history of vascular problems or high blood pressure will be evaluated by the research physician. In addition, laboratory tests collecting information on blood alcohol content and urine toxicology will be conducted. Participants will be deemed ineligible to participate if they are not medically cleared by research clinician. Veterans who have a positive BAC will be rescheduled and the methadone maintenance program's clinical protocol will be implemented.

All sessions will be conducted at the West Haven VA Connecticut Healthcare Campus. Participants will be asked to complete two sessions, approximately 2-15 days apart. Order of peak and trough sessions will be counterbalanced between participants. Each session will last approximately four hours. Prior to each testing session, participants will be asked to refrain from caffeine for at least one hour. They will be served a standardized breakfast (i.e., bagel and cream cheese) and offered one smoke break prior to beginning the experimental session. They will be asked to refrain from smoking until the completion of the study protocol. Methadone administration will be coordinated with methadone maintenance treatment staff to relay information about which condition the participant will complete on a given session. At the start of each session, participants will complete computerized cognitive assessments and self-report questionnaires. The computerized cognitive measures will repeated at hours 0, 1.5, and 3. Several state questionnaires will be administered at hours every 30 minutes. Participants will also complete a pain sensitivity measure (i.e., cold pressor task) to assess baseline threshold and tolerance at hour 0 and hour 4.

This study is complete with 27 enrolled and 20 completers.
The Flow therapeutic algorithm will be responsible for adjustment of intraoperative interventions - volumotherapy and administration of vasoactive drugs, with the aim to maintain the CI value \>2.5 l/m/m2 (FTc - flow time \<330 ms was chosen as variable defining preload; PV, peak velocity \<70 ms-1 will be used as a variable defining contractility; SVR, total systemic vascular resistance between 1000-1800 cdyn.s/cm5m2 will be used as variable defining after load). After the desired values of CI have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
The current worldwide epidemic of obesity puts millions of people at increased risk for cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM), and while insulin resistance has been a traditional focus of treatment, resistance to catecholamines in obesity is likely a key factor hampering weight loss efforts. Catecholamines are key drivers of lipolysis in adipose tissue and bind to beta-3 adrenergic receptors (ADRB3) on the surface of adipocytes. Chronic inflammation is characteristic of obesity and suppresses the expression of adipocyte ADRB3, increasing fat storage. This leaves adipose tissue metabolically inflexible and in a state of energy preservation instead of burning fat to promote and maintain weight loss. Thus, catecholamine resistance of adipose tissue is an important target for lifestyle and therapeutic intervention. Time-restricted eating (TRE) is a therapeutic intervention that promotes weight loss and healthier metabolism by aligning dietary intake with circadian rhythms. In this RCT, individuals with obesity will be enrolled in a 14-week study of TRE and behavioral nutritional counseling vs behavioral nutritional counseling alone. In the TRE group, dietary intake will be limited to a self-selected 10-hour window. Information will be collected about adipose tissue catabolism (lipolysis) using samples collected by adipose tissue biopsy of subcutaneous abdominal adipose tissue.
For pediatric patients with cancer, a healthy lifestyle is important for treatment outcomes and beyond. General pediatricians play a major role in the care of these patients, particularly given the improved rates of survival. Pediatric obesity has many negative consequences, but it is an area where primary care providers can make an impact and provide support to childhood cancer survivors. To provide the best quality of care for this population, there must be collaboration between primary care and oncology providers. Additionally, general practioners should feel empowered to offer standard nutrition and physical activity recommendations to all childhood cancer survivors. For pediatric patients who carry a cancer diagnosis, cure is no longer the only goal. Pediatric providers across specialties need to work as a team to improve long-term quality of life for these patients, starting with modifiable healthy habits.
The borderline personality disorder (BPD) is a very common personality disorder which concerns about 1.35% of total population. It is characterized by an affective, emotional, social and professional instability and an important association with comorbidities like mood disorders, post-traumatic stress disorder, addictive problems and suicide mortality. Hallucinations seem to be frequent in this personality disorder, but are not often taken in consideration by nursing staff because of massive need of attention of this kind of patient. At this moment there is no study of prevalence of this trouble in France in free environment. In the same way, there is no qualitative study about hallucinations. That is why we can do a lot of progress in this part of psychiatry.

This research is an observational study of descriptive type. Patients will be recruited in the different services. In this study, patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations.

For that, the investigator will meet each patient twice, after information by the medical staff of the service and consent. During the first meeting, the investigator will get the socio-demographic characteristics, the verification of inclusion and non-inclusion criteria, and the DIB-R questionnaire to know if the patient has really BPD and hallucinations or not. This is the same interview for all patients. During the second meeting, we will look for dissociative symptoms with DES II questionnaire, then traumatic symptoms and post-traumatic stress disorder with THQ and PCL-S. The PSAS and qualitative questionnaire will be used for BPD patients with hallucinations.
BACKGROUND: There is little experience on the use of the WHO Standards for improving the quality of care (QOC) for children. We describe the use of four prioritised WHO Standard-based Quality Measures to assess the provision of care for children with pain in emergency departments (EDs).
METHODS: In a multicentre observational study in 10 EDs with different characteristics in Italy, we collected data on 3355 children accessing the EDs between January 2019 and December 2020. The association between children and facility characteristics and quality measures was analysed through multivariate analyses.
RESULTS: The proportion of children whose pain was measured was 68.7% (n=2305), with extreme variations across different centres (from 0.0% to 99.8%, p<0.001). The proportion of children treated for pain was 28.9% (n=970) again with a wide range (5.3%-56.3%, p<0.001). The difference between the frequency of children with pain measured and pain treated varied widely between the facilities (ranging from -24.3 to 82). Children with moderate and severe pain were more frequently treated (48.9% and 62.9% of cases, respectively), although with large variations across centres (ranges: 0%-74.8% and 0%-100% respectively, p<0.001). After correction for children's characteristics, the variable more strongly associated with analysed outcomes was the facility which the child accessed for care. Being a facility in Northern Italy was associated with a higher rate of pain measurement (67.3%-95% CI: 39.9% to 94.6%, p<0.001) compared with facilities in South Italy (-22.1% lower (95% CI: -41.7% to -2.50%, p=0.03).
CONCLUSIONS: The use of few WHO Standard-based measures related to pain can help identifying priority gaps in QOC for children and in monitoring it over time. There is a need for more implementation research to establish which are the most sustainable and effective interventions to improve the QOC for acute pain in children.
The invention discloses an indol-pyrrolidine-2-ketone alkaloid and a preparation method and application thereof. The indol-pyrrolidine-2-ketone alkaloid is obtained after fermentation, extraction, chromatography and purification by using a Penicilliumramigena, YNCA0361 bacterial strain, the molecular formula of the indol-pyrrolidine-2-ketone alkaloid is C21H24N2O7, the structural formula of the indol-pyrrolidine-2-ketone alkaloid is FORMULA, and the compound is called after aspergillineD; the preservation number of the Penicilliumramigena, YNCA0361 bacterial strain is CGMCC (China General Microbiological Culture Collection Center) No. 4824, and the preservation date is May 2nd, 2011. By taking the solid yeast of the Penicilliumramigena, YNCA0361 bacterial strain as a raw material, the preparation method comprises the steps of organic solvent extraction, slica column chromatography and high pressure liquid chromatography separation. The application is that the alkaloids compound is applied to the preparation of anticancer and anti-tobacco mosaic virus drugs. The compound is novel in structure and good in activity, can serve as an anticancer drug or a lead compound for resisting tobacco mosaic virus, and has a better application prospect.
The invention discloses a whitening strip suitable for all age groups of persons to use externally. The nutrient whitening strip comprises the following main ingredients: vitamin C derivatives, arbutin, liquorice essence and mulberry extract liquor. The whitening strip adopts an adhesive composed of a novel elastomer material styrene-isoprene-styrene (SIS) triblock copolymer, a tackifier and a plasticizer as a cosmetic matrix material. The novel whitening strip for external use can be prepared into different shapes by applying the low-temperature online melting forming technology, thus being suitable for different age groups of persons to use in different positions. The nutrient whitening strip for external use has clear ingredient efficacy, good transdermal permeability and soft texture, can be released permanently, and is of high elasticity. The whitening strip can directly reach the skin layer to achieve the effects of long-time whitening, moisturizing, skin relieving and the like.